Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,741,291 papers from all fields of science
Search
Sign In
Create Free Account
canakinumab 180 MG Injection [Ilaris]
Known as:
CANAKINUMAB 150 mg in 1 mL SUBCUTANEOUS INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [Ilaris]
, ILARIS 180 MG Injection
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
7 relations
Histidine
Injection
Polysorbate 80
Sucrose
Expand
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Canakinumab (ILARIS®) in cryopyrin-associated periodic syndrome (CAPS)patients below 2 years of age: Review of four cases and literature.
D. Vana
2017
Corpus ID: 4147550
Cryopyrin-Associated Periodic Syndrome (CAPS) is combination of different autoinflammatory hereditary disorders with same genetic…
Expand
2014
2014
Опыт применения ингибитора интерлейкина 1β канакинумаба у больного с хронической тофусной подагрой
Array С. Елисеев
,
Array Желябин
,
Array Г. Барскова
,
A. Насонов
RSP
2014
Corpus ID: 59925804
This article reports a clinical case of administration of canakinumab (Ilaris®), an interleukin-1β inhibitor, in a patient with…
Expand
Review
2013
Review
2013
FRI0430 Comparative effectiveness and health economic evaluation of systemic anti-inflammatory therapies for acute GOUT flares
K. Reiter
,
E. Krishnan
,
J. Goldhaber-Fiebert
2013
Corpus ID: 75255163
Background There have been few published comparisons of various treatment options for acute gout flares that incorporate costs…
Expand
2013
2013
THU0392 Beta-confident-registry: Efficacy and safety of canakinumab in cryopyrin associated periodic syndrome - 18 month follow-up
J. Kuemmerle-Deschner
,
P. Hawkins
,
H. Hoffman
,
T. van der Poll
,
U. Walker
,
H. Tilson
2013
Corpus ID: 75476966
Background Canakinumab (CAN, Ilaris®), a fully human anti-IL-1β monoclonal antibody, selectively inhibits IL-1β and has been…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE